Adaptimmune stock plunges after announcing Nasdaq delisting plans
Investing.com - Becton Dickinson (NYSE:BDX), the $51.7 billion medical technology company currently trading at a P/E ratio of 34.15, announced disappointing preliminary fourth-quarter sales results and the upcoming departure of its Chief Financial Officer, according to a company statement released Wednesday.
The medical technology company reported that its fiscal fourth-quarter sales fell below consensus estimates, though specific figures were not disclosed in the announcement. This comes despite the company’s solid 7.86% revenue growth over the last twelve months. Simultaneously, the company revealed that CFO Chris DelOrefice will leave on December 5 "to pursue another opportunity."
Stifel maintained its Buy rating on Becton Dickinson with a $224.00 price target despite the disappointing news. The research firm suggested that current fiscal 2026 estimates are likely too high and that the company will probably take a cautious approach to forward guidance.
The company’s financial position remains solid with modest net leverage of 2.8x and substantial annual free cash flow exceeding $2 billion, according to Stifel’s analysis. The research firm also noted that the planned separation of the Diagnostic Solutions & Biosciences business represents a positive development.
Becton Dickinson’s announcement comes as the company continues its strategic transformation efforts, though the CFO departure adds uncertainty regarding the company’s fiscal 2026 guidance outlook. According to InvestingPro analysis, the stock appears to be trading below its Fair Value, suggesting potential upside despite current challenges.
In other recent news, Becton Dickinson released preliminary fourth-quarter results for fiscal 2025, which showed revenue and earnings per share slightly below the low end of its previous guidance. RBC Capital reiterated a Sector Perform rating on the company’s stock, maintaining a cautious outlook as the company undergoes a CFO transition. In a strategic move, Becton Dickinson plans to spin off and merge its Biosciences and Diagnostics businesses with Waters in the first quarter of 2026. RBC Capital initiated coverage with a Sector Perform rating and a $211.00 price target, reflecting on these restructuring plans.
Additionally, Becton Dickinson has enrolled the first patient in its XTRACT Registry study to evaluate the Rotarex Catheter System for peripheral artery disease treatment. The company also announced a multi-year partnership with Opentrons Labworks to automate single-cell research workflows, integrating robotic liquid-handling capabilities into BD’s instruments. Furthermore, Becton Dickinson has partnered with Henry Ford Health to automate pharmacy services, deploying the BD Rowa Vmax system for 24/7 prescription pickups in Michigan. These developments reflect Becton Dickinson’s ongoing efforts to innovate and expand its technological capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.